BioNTech SE (BNTX) annual results, year to 31 December 2025: revenue EUR 2,870 million, from the 20-F
BioNTech SE files a 20-F with the SEC once a year, in euros. In the year to 31 December 2025 it reported revenue of EUR 2,870 million ($3.2 billion at the year's average rate), up 4.3% on the year before. Its profit attributable to shareholders was EUR -1,136 million, and diluted earnings per share EUR -4.70.
The year to 31 December 2025, against the year before
| Year to | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 2,751 | 2,870 |
| Cost of sales | 541 | 642 |
| Research and development | 2,254 | 2,105 |
| Operating profit | -1,314 | -1,405 |
| Finance costs | 27.4 | 69.8 |
| Profit before tax | -678 | -1,051 |
| Income tax | -12.4 | 85.3 |
| Profit for the year | -665 | -1,136 |
| Profit attributable to shareholders | -665 | -1,136 |
| Filing | 20-F | 20-F |
EUR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
EUR per ordinary share, as filed.
Cash flow
| Year to | Dec 2024 | Dec 2025 |
|---|---|---|
| Cash from operations | 208 | 456 |
| Purchase of property, plant and equipment | 286 | 175 |
| Free cash flow | -78.8 | 281 |
| Dividends paid | 0.0 | n/a |
| Filing | 20-F | 20-F |
EUR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2024 | Dec 2025 |
|---|---|---|
| Total assets | 22,530 | 21,989 |
| Equity attributable to shareholders | 19,411 | 19,224 |
| Cash and cash equivalents | 9,762 | 7,675 |
| Lease liabilities | 254 | 230 |
| Trade and other receivables | 1,464 | 924 |
| Inventories | 283 | 111 |
| Goodwill | 381 | 368 |
| Filing | 20-F | 20-F |
EUR million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating margin | -47.8% | -49.0% |
| Net margin | -24.2% | -39.6% |
| Free cash flow margin | -2.9% | 9.8% |
| Return on year-end equity | -3.4% | -5.9% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
The exchange rates used
| Year to | Average over the year US dollars per EUR | At the year end US dollars per EUR |
|---|---|---|
| Dec 2017 | 1.1301 | 1.2022 |
| Dec 2018 | 1.1817 | 1.1456 |
| Dec 2019 | 1.1194 | 1.1227 |
| Dec 2020 | 1.1410 | 1.2230 |
| Dec 2021 | 1.1830 | 1.1318 |
| Dec 2022 | 1.0534 | 1.0698 |
| Dec 2023 | 1.0817 | 1.1062 |
| Dec 2024 | 1.0820 | 1.0351 |
| Dec 2025 | 1.1306 | 1.1736 |
Converted by us, not by the company: the Federal Reserve's daily noon buying rates in New York (H.10), FRED series DEXUSEU. Profit and loss, cash flow and EPS use the average of the daily rates over each fiscal year; the balance sheet uses the rate on the year end, or the last one before it. Ratios are the same in either currency. The filed figures are the ones in euros.
Every annual report here
- Year to 31 December 2025, this page
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017
Source
20-F for the year to 31 December 2025, filed 30 July 2026, accession 0001776985-26-000049: the filing on EDGAR. All of BioNTech SE's filings: EDGAR company page. The figures are in euros as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.